A phase 2 substudy found retatrutide produced dose-related reductions in total body fat mass at 36 weeks versus placebo and dulaglutide in type 2 diabetes. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A post hoc mediation analysis of the SURMOUNT-1 to -4 trials found that gastrointestinal adverse events contributed only slightly (up to 3.1%) to tirzepatide-associated weight reduction, which was similar regardless of nausea. PICO summary and expert commentary.
A small acute mechanistic crossover study testing whether exenatide-glucagon co-infusion raises myocardial glucose uptake and a diastolic strain-rate marker in eight adults with type 2 diabetes. PICO summary and expert commentary.
An exploratory post hoc analysis suggesting tirzepatide improves insulin sensitivity more per unit weight loss than semaglutide in type 2 diabetes. PICO summary and expert commentary.
A secondary analysis of the COORDINATE-Diabetes trial found that up to one-third of patients with Type 2 diabetes and atherosclerotic cardiovascular disease stopped their SGLT-2i or GLP-1RA within 12 months, with cost and side effects among the cited reasons. PICO summary and expert commentary.
A post hoc analysis of the ADJUNCT ONE and ADJUNCT TWO trials identifies who discontinues adjunctive liraglutide in type 1 diabetes: longer disease duration, undetectable C-peptide, and lower BMI. PICO summary and expert commentary.
A post hoc analysis of the DIVERSITY-CVR trial tests whether baseline ALT predicts differential HbA1c and time-in-range responses to dapagliflozin versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
An early-phase trial of the GLP-1/FGF21 dual agonist HEC88473 reported dose-proportional liver fat reduction and improved glycaemic control over 5 weeks in patients with MASLD and type 2 diabetes. PICO summary and expert commentary.
A 16-week randomized trial found combined training lowered GLP-1 and amylin and raised DPP-4 in adults with type 2 diabetes and overweight, without a demonstrated glycaemic benefit. PICO summary and expert commentary.
A phase 1, double-blind, placebo-controlled study of titrated noiiglutide (SHR20004) in obese Chinese adults without diabetes reported good tolerability and dose-related weight loss, with PICO summary and expert commentary.